ReviewNeuro-oncology advances
Seizure outcomes as an understudied metric in glioma clinical trials: A review of the ClinicalTrials.gov database.
Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Seizure-Related Deterioration in Treated Glioma: A Narrative Review of Nonconvulsive Status Epilepticus, Peri-Ictal Pseudoprogression, Treatment-Related Change, and True Progression.Diagnostics (Basel, Switzerland) · 2026Review
- Neuro-glioma activity-dependent growth mechanisms: an actionable circuit from NLGN3-ADAM10 to AMPA synapses.Translational cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Abstract: BackgroundSeizures are a common and disabling symptom of adult-type diffuse gliomas, affecting quality of life and potentially influencing tumor progression. Despite their clinical significance, seizure outcomes are often underreported or heterogeneously measured in clinical trials. Objective: To assess how seizure outcomes are reported in clinical trials for adult-type diffuse glioma. Methods: We systematically reviewed glioma clinical trials initiated after January 1, 2010, through June 16, 2025, on ClinicalTrials.gov that included seizure-related outcomes. Each trial was manually screened to characterize how seizures were defined, measured, and categorized. Results: Of 2,801 clinical trials identified, 65 (2.3%) included seizure-related outcomes. Among these, 20 designated seizures as a primary outcome, though many grouped them within broader safety endpoints. Seizures were often listed as secondary outcomes ( Conclusions: Despite their clinical significance, seizure outcomes are rarely and heterogeneously reported in clinical trials for adult-type diffuse gliomas. Incorporating standardized, seizure-specific endpoints may better align glioma research with patient-centered and disease-specific outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.